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closely mimicked the p62-positive neuronal cytoplasmic 
inclusions commonly observed for all DPR proteins in 
patients. In contrast, overexpressed poly-GR and poly-
PR formed nucleolar p62-negative inclusions. In patients, 
most of the less common neuronal intranuclear DPR 
inclusions were para-nucleolar and p62 positive. Neu-
ronal nucleoli in C9orf72 cases showed normal size and 
morphology regardless of the presence of poly-GR and 
poly-PR inclusions arguing against widespread nucleo-
lar stress, reported in cellular models. Colocalization of 
para-nucleolar DPR inclusions with heterochromatin and 
a marker of transcriptional repression (H3K9me2) indi-
cates a link to gene transcription. In contrast, we detected 
numerous intranuclear DPR inclusions not associated 
with nucleolar structures in ependymal and subependy-
mal cells. In patients, neuronal inclusions of poly-GR, 
poly-GP and the poly-GA interacting protein Unc119 
were less abundant than poly-GA inclusions, but showed 
similar regional and subcellular distribution. Regardless 
of neurodegeneration, all inclusions were most abun-
dant in neocortex, hippocampus and thalamus, with few 
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inclusions in brain stem and spinal cord. In the granular 
cell layer of the cerebellum, poly-GA and Unc119 inclu-
sions were significantly more abundant in cases with 
FTLD than in cases with MND and FTLD/MND. Poly-
PR inclusions were rare throughout the brain but signifi-
cantly more abundant in the CA3/4 region of FTLD cases 
than in MND cases. Thus, although DPR distribution is 
not correlated with neurodegeneration spatially, it corre-
lates with neuropathological subtypes.
Keywords ALS · FTLD · Repeat disorders · C9orf72 · 
DPR inclusions · Neurotoxicity
Introduction
About 10 % of all patients with amyotrophic lateral scle-
rosis (ALS), frontotemporal dementia (FTD) or mixed 
presentation of both diseases (ALS/FTD) are caused by a 
massive expansion of a GGGGCC repeat upstream of the 
C9orf72-coding region [11, 18, 43]. Three main hypoth-
eses have been proposed to explain the pathomechanism 
of C9orf72 disease. First, reduced expression of the 
mutant allele suggests a loss of function mechanism [11, 
18]. Studies in C. elegans and zebrafish reported motor 
deficits [7, 51], although loss of C9orf72 has no obvious 
effect in cultured neurons and mice [25, 55]. Second, the 
repeat RNA may induce toxicity by sequestering endog-
enous RNA-binding proteins in nuclear RNA foci [16]. 
A large number of GGGGCC-interacting proteins have 
been identified, but their contribution to C9orf72 dis-
ease has not been elucidated so far [9, 27, 37]. Addition-
ally, formation of RNA·DNA hybrids of the expanded 
repeat (so-called R-loops) may contribute to toxicity by 
interfering with transcription [20, 54]. However, in cul-
tured primary neurons and the fly retina even high-level 
expression of repeat RNA causes little or no toxicity [35, 
55]. Third, although located in an intron and lacking an 
ATG start codon, sense and antisense transcripts of the 
expanded repeat are translated by an unconventional 
mechanism into five dipeptide repeat (DPR) protein spe-
cies [1, 17, 36, 38, 60]. All DPR species are detected 
in neuronal inclusions throughout the central nervous 
system (CNS) of C9orf72 mutation patients, predomi-
nantly in the cytoplasm. Inclusions of poly-(glycine–
alanine) (poly-GA), poly-(glycine–arginine) (poly-GR) 
and poly-(glycine–proline) (poly-GP) proteins encoded 
by the sense strand are far more abundant than poly-
(proline–alanine) (poly-PA) and poly-(proline–arginine) 
(poly-PR) proteins encoded by the antisense strand 
[17, 36]. None of these mechanisms, however, has so 
far explained the origin of neuronal and glial TDP-43 
inclusions found in almost all cases with C9orf72 muta-
tion, and the variable expression of dementia and motor 
symptoms even within the same family [16, 33]. Inter-
estingly, the first clinical symptoms and neurodegenera-
tion seem to arise prior to the onset of TDP-43 pathology 
when DPR inclusion pathology is already widespread [2, 
36, 38, 42].
Recently, several groups reported toxicity of recom-
binantly expressed individual DPR species in cell lines, pri-
mary neurons and the fly retina. This led to a controversy 
about the main toxic DPR species. Several groups showed 
neurotoxicity of poly-GA, the most abundant DPR inclu-
sion protein in C9orf72 mutation patients. Poly-GA toxic-
ity has been attributed to co-aggregation of the transport 
factor Unc119 [34] and impairment of the proteasome [57, 
59]. However, in contrast to TDP-43 inclusions, poly-GA 
inclusions show no spatial correlation with neurodegenera-
tion in patients [10, 29]. Other reports favor toxicity of the 
arginine-rich DPR species, poly-GR and poly-PR, by inter-
ference with global RNA metabolism and protein synthesis 
[23, 35, 55]. While poly-GR and poly-PR localization was 
not analyzed in the fly model [35], cell culture studies found 
overexpressed poly-GR and poly-PR (20–400 repeats) pre-
dominantly in nucleolar aggregates [23, 34, 55, 57, 59]. 
This is in strong contrast to the predominantly cytoplasmic 
localization of poly-GR and poly-PR described in patients 
so far [17, 36, 38, 60]. Poly-GP also has been reported to 
induce toxicity in cell lines, although no mechanism was 
proposed [60]. Only poly-PA was not toxic in any system 
tested. However, none of the proposed pathomechanisms 
has been rigorously validated in patient tissue.
Prompted by conflicting reports on the neurotoxic-
ity of DPR proteins in vitro, we carefully compared the 
expression of recombinant DPR proteins in primary rat 
neurons of all DPR species with proposed neurotoxic-
ity, including the predominant sense strand-derived DPR 
inclusions and poly-PR, in patient brain using novel 
monoclonal antibodies particularly focusing on nuclear 
and nucleolar pathology. Since toxic overexpressed argi-
nine-rich DPRs mainly aggregate in p62-negative intra-
nuclear inclusions, we tried to identify such inclusions 
in key areas of neurodegeneration in patient CNS. Addi-
tionally, we analyzed the regional distribution pattern 
of aggregates containing poly-GA, its interacting part-
ner Unc119, poly-GR, poly-GP or poly-PR in brain and 
spinal cord of autopsy cases with C9orf72 mutation and 
correlated aggregate frequency with the neuropathologi-
cal diagnosis.




The following antibodies were used: anti-nucleolin (rab-
bit polyclonal and mouse monoclonal, Abcam, Cam-
bridge England), anti-p62/SQSTM1 (rabbit polyclonal, 
MBL, Nagoya Japan and mouse monoclonal, BD, Bel-
gium), anti-poly-GA clone 5E9 (mouse monoclonal) [29], 
anti-Unc119 (rabbit polyclonal, homemade) [34], anti-
fibrillarin (rabbit polyclonal, Abcam), anti-GST (rabbit 
polyclonal, Eurogentec, Belgium), anti-H3K9me2 (Cell 
Signaling Technology, Cambridge, England), anti-HDAC6 
(Santa Cruz, Dallas, Texas), anti-CUG-BP1 (Abcam), anti-
PML (Abcam), anti-HSF1 (Santa Cruz), anti-CD99/MIC2 
(Thermo scientific, Waltham, Massachusetts), anti-PSMC2 
and anti-PSMC4 (Bethyl laboratories, Montgomery, Texas), 
anti-Coilin (Abcam) and anti-p53 (Ventana, Tuscon, 
Arizona). Poly-GR antibodies 5A2 and 5H9 have been 
described previously [36, 38]. The novel poly-GR-specific 
clone 7H1 (rat isotype IgG2c) was identified by rescreening 
monoclonal antibodies raised against the EBNA2 epitope 
GQSRGRGRGRGRGRGKGKSRDK with asymmetri-
cally dimethylated arginines [19] and screened by ELISA 
against biotinylated (GR)10 peptides (Peps4LifeSciences, 
Heidelberg, Germany) as described [36]. Like clone 5H9, 
7H1 detected (GR)10 with asymmetrically dimethylated 
arginines and non-methylated arginines, but also weakly 
cross-reacts with (GR)10 containing symmetrically dimeth-
ylated arginines (data not shown). By immunizing rats with 
synthetic GP10 peptides the poly-GP-specific antibody 7A5 
(isotype IgG2c) was raised using previously described pro-
tocols [29]. Poly-PR antibody 32B3 (isotype IgG2b) was 
raised against synthetic PR10 peptides in mouse using the 
same protocol.
RNA was stained with SYTO12 and SYTO RNAselect 
(Life Technologies, Darmstadt, Germany) and nuclei were 
stained with DAPI (Roche Applied Science, Penzberg, 
Germany).
DNA constructs and lentivirus production
Previously described cDNAs of GA175-GFP and GFP-
GR149, GP80-V5/His and PR175-GFP with ATG start codon 
were cloned in a lentiviral packing vector (FhSynW2) 
containing the human synapsin promoter [34]. Poly-GA, 
poly-GR and poly-PR were expressed from synthetic genes 
devoid of GGGGCC repeats, while poly-GP was expressed 
from a ATG(GGGCCG)80 construct. For poly-GR, the GFP 
had to be fused to the N-terminus to allow robust expres-
sion (for details see [34]). Lentivirus was produced in 
HEK293FT cells (Life Technologies) as described previ-
ously [15].
Cell culture
Primary hippocampal and cortical neurons were cultured 
from embryonic day 19 rats and infected for transduction 
with lentivirus as described previously [15, 48]. For immu-
nofluorescence, the primary neurons were fixed for 10 min 
in 4 % paraformaldehyde and 4 % sucrose on ice. Primary 
and secondary antibodies were diluted in GDB buffer 
(0.1 % gelatin, 0.3 % Triton X-100, 450 mM NaCl, 16 mM 
sodium phosphate pH 7.4). Confocal images were taken 
by a LSM710 confocal laser scanning system (Carl Zeiss, 
Jena, Germany) with a 63× oil immersion objective.
Patient material, brain slices
Tissue samples of all autopsy cases investigated were pro-
vided by the Neurobiobank Munich, Ludwig-Maximilians-
University (LMU) Munich. They were collected according 
to the guidelines of the local ethical committee. Demo-
graphic and neuropathological data are listed in Table 1.
Definition of neuropathological groups
Cases with C9orf72 mutation were stratified into fronto-
temporal lobar degeneration (FTLD), motoneuron disease 
(MND) or mixed FTLD/MND according to neuropatho-
logical criteria. FTLD was diagnosed when gliosis and/or 
spongy alterations were seen in the cortex of the superior 
Table 1  Demographic and neuropathological data of patients and 
control cases




C9-1 Female 65 3 years FTLD–MND
C9-2 Female 59 6 months FTLD–MND
C9-3 Male 65 4 years FTLD–MND
C9-4 Female 63 3 years MND
C9-5 Female 49 8 months MND
C9-6 Male 51 2 years MND
C9-7 Male 72 1 years FTLD
C9-8 Female 57 7 years FTLD
C9-9 Male 67 Unknown FTLD
C9-10 Male 41 6 years FTLD–MND
C9-11 Male 56 22 months FTLD–MND
C9-12 Male 57 3 years FTLD–MND
C9-13 Male 57 3–4 years FTLD–MND
C9-14 Male 74 Several years FTLD–MND
FUS-1 Female 54 4 years FTLD–MND–
FUS
Ctrl-1 Male 60 – –
Ctrl-2 Female 60 – –
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and/or medial frontal gyrus (Brodman areas 8/9) and/or in 
the cortex of the parahippocampal and/or fusiform gyrus 
on hemalum–eosin stainings. MND was diagnosed when 
either the motor cortex showed gliosis and/or spongy alter-
ations on hemalum–eosin stainings and/or the pyramidal 
tract showed a microglia activation on immunohistochemi-
cal stains using the CR3/43 antibody and/or the hypoglos-
sal nucleus and/or the anterior horn at any spinal cord 
level showed a loss of motoneurons and/or gliosis and/or 
p62-positive inclusions in motoneurons.
Immunohistochemistry
Immunohistochemistry and immunofluorescence were per-
formed on paraffin sections as previously described [29]. 
For Unc119 immunohistochemistry, paraffin sections were 
treated 25 min with 0.1 µg/μl proteinase K in 10 mM Tris/
HCl. This pretreatment dramatically increased the number 
of visible Unc119 aggregates (compare [34]). Afterwards 
the slides were incubated with the Unc119 antibody over-
night at 4 °C and detected with the DCS SuperVision 2 Kit 
(DCS innovative diagnostic-system, Hamburg, Germany) 
according to the manufacturer’s instructions. An additional 
0.05 µg/µl proteinase K pretreatment for 1 min before cit-
rate retrieval was used for anti-nucleolin and H3K9me2 
immunofluorescence experiments. Anti-poly-GA immu-
nohistochemistry was performed with the Ventana Bench-
Mark XT automated staining system (Ventana) using the 
UltraView Universal DAB Detection Kit (Roche). Incuba-
tion with poly-GR and poly-GP antibodies was done over-
night at 4 °C, further steps were an incubation with a rab-
bit anti-rat antibody (1:2000) for 1 h at room temperature, 
and a final processing on the Ventana BenchMark XT using 
the UltraView Universal DAB Detection Kit (Roche). The 
poly-PR antibody was also incubated overnight at 4 °C 
and detected the following day on Ventata BenchMark XT. 
Images of immunohistochemical stainings were taken by 
CellD, Olympus BX50 Soft Imaging System (Olympus, 
Tokyo, Japan), confocal images on a LSM710 (Carl Zeiss) 
with a 40× or 63× oil immersion objective.
RNA in situ hybridization
Paraffin sections were dewaxed in xylene and ethanol fol-
lowed by microwaving in citrate pH6 buffer for 4 × 5 min. 
After washing with 2× SSC (0,3 M NaCl, 30 mM sodium 
citrate, pH7), sections were preincubated (30 min) at 65 °C 
in 2× SSC containing 40 % formamide and 2.5 % BSA and 
incubated over night at 50 °C with the Cy3(GGCCCC)4 
probe (Integrated DNA Technologies, Coralville, Iowa) in 
2× SSC containing 0.8 mg/ml tRNA, 0.8 mg/ml salmon 
sperm DNA, 0.16 % BSA, 8 % dextran sulfate, 1.6 mM 
ribonucleoside vanadyl complex and 5 mM EDTA. After 
washing with 0.5× SSC immunofluorescence was per-
formed as described previously [29]. In all steps, RNase-
free Milli-Q ultrapurified water was used.
Semi‑quantitative analysis of inclusion pathology
Frequency of poly-GA, poly-GR, poly-GP and Unc119 
inclusion pathology was analyzed separately for neuronal 
cytoplasmic inclusions (NCI), neuronal intranuclear inclu-
sions (NII) and dystrophic neurites (DN) in a semi-quan-
titative manner for 36 different CNS regions of five repre-
sentative cases (C9-1 to 5) with C9orf72 mutation with a 
Zeiss Axioplan microscope. In neocortical regions, in the 
granular and molecular cell layers of the cerebellum and in 
spinal cord, each type of inclusion pathology was consid-
ered as “few” if less than half of 12 representative visual 
fields (using a 20× objective) showed at least one inclu-
sion, as “some” if more than half but not all visual fields 
showed at least one inclusion, as “many” if in every visual 
field at least 4 inclusions were detectable and as “abun-
dant” if each visual field showed more than 20 aggregates. 
This method was also used for counting dystrophic neur-
ites in all regions. In structures of hippocampus, subcortical 
nuclei, brain stem and the Purkinje cell layer of the cerebel-
lum, NCIs and NIIs were considered as “few” if less than 
2 % of the neurons contained aggregates, “some” if 3–25 % 
of the neurons contained aggregates, “many” if 25–50 % of 
the neurons contained aggregates and “abundant” if more 
than 50 % of the neurons contained aggregates.
Quantitative analysis of inclusion pathology
The following areas with high loads of DPR protein aggre-
gates but diverging neurodegenerative vulnerability were 
selected for quantification of NCIs and NIIs: cortex of 
the superior frontal gyrus, motor cortex, striate area of the 
occipital cortex, granular cell layer of the dentate gyrus, 
cornu ammonis regions 3/4, granular cell layer of the cer-
ebellum, molecular cell layer of the cerebellum (superior 
part).
In all cases with C9orf72 mutation, 3–12 pictures adja-
cent to each other were taken from a representative area 
of each region of interest with a digital camera (Olympus 
Cam SC30) at an Olympus BX41 microscope using a 40× 
objective for cerebellar granular cell layer and a 20× objec-
tive for all other regions. Three to four pictures were taken 
from each cerebellar and hippocampal region. In neocortex, 
pictures were taken in a columnar orientation covering all 
six cell layers. The inclusions of one such column repre-
sented by 6–12 adjacent pictures were counted. All NCIs 
and NIIs were manually counted on each digital picture 
separately using the CellCounter plugin in Fiji ImageJ. For 
each region in each case, the total number of inclusions was 
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divided by the number of pictures taken, and the average 
value was determined. Finally, the average of the values 
for each region was determined in each neuropathological 
group (FTLD, MND, FTLD/MND) separately.
Statistics
Statistical analysis was performed with GraphPad Prism 
software (version 6.01). The groups with neuropathological 
diagnosis MND, FTLD and FTLD/MND were compared 
and analyzed by two-way ANOVA followed by Tukey’s 
post hoc test. Nucleolus size (Feret diameter) was quanti-
fied from confocal images, taken on a LSM710 with a 40× 
oil immersion objective, using Fiji ImageJ particle analyzer 
and statistically evaluated by an unpaired t test followed by 
an F-test to compare variances. Multiple comparison of the 
size of the nucleoli in the frontal cortex was done by one-
way ANOVA followed by Tukey’s post hoc test. Signifi-
cance level was set at p < 0.05 (two sided).
Results
Intranuclear poly‑GR and poly‑PR inclusions are 
nucleolar in cell models, but para‑nucleolar in patients
To compare DPRs expressed from synthetic genes and 
DPR inclusions in C9orf72 mutation patients under opti-
mal conditions, we raised novel monoclonal antibodies. 
Rat poly-GP antibody 7A5, rat poly-GR antibody 7H1 and 
mouse poly-PR antibody 32B3 specifically detected the 
respective 15-mer DPRs fused to GST (Fig. S1a). 7A5 and 
7H1 robustly detected SDS-insoluble aggregates in frontal 
cortex of patients but not of controls cases (Fig. S1b). In 
patients, poly-GR antibody 7H1 detected more neuronal 
cytoplasmic inclusions than the previously used clone 5H9 
(Fig. S1c). The monoclonal poly-GP and poly-PR antibod-
ies also allowed a more sensitive detection of poly-GP and 
poly-PR inclusions than our previous polyclonal antibod-
ies [36, 38]. With the new antibodies, poly-GR and poly-
GP aggregates were found in various brain areas and in 
spinal cord motoneurons of C9orf72 mutation patients, but 
not of control cases (Fig. S2a, b). Poly-PR inclusions were 
much less common in all brain regions (Fig. S2c). Despite 
a recent report of preferential aggregation of poly-PR in 
spinal cord motoneurons [8], we found no such inclusions 
with both the mouse poly-PR antibody 32B3 and our rabbit 
polyclonal antibody [39].
To analyze the DPR proteins in vitro, we transduced rat 
hippocampal neurons with a lentivirus expressing GFP-
GR149, PR175-GFP, GA175-GFP or GP80-V5/His for 7 days. 
Consistent with previous results [34, 57, 59], GFP-GR149 
showed a diffuse cytoplasmic distribution and often formed 
nuclear aggregates that colocalized with nucleolin, a key 
component of the nucleolus (Fig. 1a, first row). PR175-GFP 
showed more pronounced nuclear and nucleolar locali-
zation and the majority of nucleoli appeared fragmented 
(Fig. 1a, second row). GA175-GFP formed compact mainly 
cytoplasmic and some intranuclear inclusions that did not 
colocalize with nucleolin (Fig. 1a, third row). GP80-V5/His 
expression was diffusely distributed throughout the neurons 
with some enrichment in the nucleus (Fig. 1a, fourth row). 
Lentiviral expression of the four DPR constructs in corti-
cal neurons fully confirmed the localization found in hip-
pocampal neurons (Fig. S3).
In contrast to transduced hippocampal neurons, poly-GR 
and poly-PR antibodies labeled mainly cytoplasmic inclu-
sions in C9orf72 mutation patients (Fig. S2a, c), an obser-
vation consistent with previous reports [17, 36, 38, 60]. 
However, a fraction of neurons also contained small poly-
GR and poly-PR inclusions in the nucleus (Fig. 1b, first 
and second row). Quantitative analysis revealed that 78 % 
of the poly-GR NIIs were attached to the nucleoli, whereas 
the remaining NIIs were randomly distributed (Fig. 1b, 
first row, Fig. S4a). In contrast to GFP-GR149 and PR175-
GFP expressing neurons, we never saw a colocalization of 
poly-GR or poly-PR and nucleolin in three C9orf72 cases 
investigated. Immunofluorescence with two other monoclo-
nal poly-GR antibodies (5H9 and 5A2) [36, 38] confirmed 
these results (Fig. S4b). Moreover, poly-GR did not colo-
calize with fibrillarin, another nucleolar marker (Fig. S4c). 
Intranuclear poly-GA and poly-GP showed a very similar 
pattern of para-nucleolar inclusions in C9orf72 mutation 
patients (Fig. 1b, rows three and four; Fig. S4a). Thus, cur-
rent cellular DPR models cannot fully replicate the pattern 
of intranuclear aggregates found in patient tissue.
Para‑nucleolar DPR aggregates colocalize with silent 
DNA
To elucidate the nature of the para-nucleolar DPR compart-
ment, we analyzed colocalization with several marker pro-
teins (data not shown). However, none of the markers for 
Marinesco bodies (HDAC6), the perinuclear compartment 
(CUG-BP1, PML, HSF1 and CD99), clastosomes (protea-
somal subunits PSMC2 and PSMC4) and nucleolar caps 
(fibrillarin, coilin and PML) colocalized with para-nucleo-
lar DPR inclusions, indicating they represent a unique com-
partment. Moreover, the para-nucleolar DPR protein aggre-
gates were also not colocalized with the nuclear GGGGCC 
RNA foci in frontal cortex or cerebellum (Fig. S4d/e). 
However, many para-nucleolar DPR inclusions colocal-
ized with heterochromatin detected by the DNA-binding 
dye DAPI in patients (Fig. 2a), which was not observed for 
poly-GA, poly-GR, poly-PR or poly-GP overexpressed in 
primary neurons (Fig. 1a). Para-nucleolar DPR inclusions 
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were also labeled by the RNA-binding dyes SYTO12 and 
SYTO RNAselect, but no RNA enrichment was observed 
compared to the nucleolus (Fig. 2b). Since all RNA dyes 
also cross-react with DNA to some extent, we focused on 
the specific enrichment of heterochromatin DNA in para-
nucleolar DPR inclusions. Colocalization was even more 
pronounced with an antibody for histone 3 dimethylated 
at lysine 9 (H3K9me2), a signal for transcriptional silenc-
ing (Fig. 2c). This may link para-nucleolar DPR proteins to 
transcriptional changes induced by the expanded C9orf72 
repeat DNA and RNA [20].
Since arginine-rich DPR proteins and transcription of 
the expanded repeat have been shown to induce nucleo-
lar stress in cellular models [20, 50], we also investigated 
nucleolar size and morphology. Nucleolin stainings of the 
CA3/4 layer of the hippocampus, a region with abundant 
DPR pathology, revealed no differences in nucleolus shape 
and size between C9orf72 patients and controls (Fig. S5a, 
b). In the frontal cortex of C9orf72 FTLD cases, the size 
of the nucleoli did not differ from nucleoli of healthy con-
trols regardless, whether the cells contained cytoplasmic or 
para-nucleolar or no DPR inclusions (Fig. S5c).
Nucleolar stress typically results in nucleolar p53 accu-
mulation [26], which we did not observe in C9orf72 cases 
(Fig. S5d). Thus, the expanded hexanucleotide repeat DNA 
and/or RNA may interfere with transcriptional processes 

























Fig. 1  Differential localization of intranuclear DPR inclusions in 
transduced primary neurons and in neurons of cases with C9orf72 
mutation. Double immunofluorescence for different DPR proteins 
(green) and nucleolin (red), a marker for the nucleolus, in primary 
neurons (a) and in frontal cortex of cases with C9orf72 mutation (b). 
Nuclei are labeled with DAPI. Single confocal sections containing 
the nucleolus are shown. a Primary neurons transduced with lentivi-
rus expressing either GFP-GR149, PR175-GFP, GA175-GFP or GP80-
V5/His (DIV6 + 7). Note that poly-GR and poly-PR but not poly-
GA intranuclear inclusions are localized in the nucleolus. Poly-GA 
forms mainly compact cytoplasmic inclusions. Poly-GP expression 
is mainly pan-nuclear and also cytosolic. b In cortical areas of cases 
with C9orf72 mutation neuronal intranuclear poly-GA, poly-GR and 
poly-GP inclusions are mostly localized adjacent to the nucleolus 
(red arrows) or less frequently randomly distributed (white arrows). 
No colocalization of DPR proteins with the nucleolus is observed. 
Scale bars represent 10 µm
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Overexpressed and patient poly‑GR, poly‑PR 
and poly‑GP show different p62 labeling
p62 is found in many inclusion bodies of neurodegenera-
tive diseases. Although most inclusions of all DPR species 
colocalize with p62 in C9orf72 patients [36, 38], we and 
others had only found a colocalization of p62 with over-
expressed poly-GA but not with other overexpressed DPR 
species in HEK293 cells [34, 57]. We therefore tested 
p62 co-aggregation in primary hippocampal neurons with 
lentiviral expression of GA175-GFP, GFP-GR149, PR175-
GFP, GP80-V5/His. Consistent with previous results, most 
cytoplasmic and intranuclear GA175-GFP inclusions were 
strongly co-labeled with p62 antibodies (Fig. 3a, first row), 
while GFP-GR149 and PR175-GFP inclusions were nega-
tive for p62 (Fig. 3a, second row and Fig. S6a). GP80-V5/
His was diffusely expressed with enrichment in the nucleus 
without obvious p62 colocalization (Fig. 3a, third row). 
These results were confirmed in cortical neurons trans-
duced with the same DPR constructs (Fig. S6b).
We wondered whether such p62-negative poly-GR 
inclusions occur in patients, particularly in the nucleo-
lus. In frontal cortex, double immunostaining revealed a 
strong colocalization of poly-GR and p62 in the cytosol 
and the nucleus, similar to poly-GA (Fig. 3b, first and 
second row, Fig. S7a, first row). Only very few poly-GR 
inclusions in the cytosol (Fig. 3b, second row) as well as 
in the nucleus (Fig. S7a, second row) were not labeled 
with p62. Similarly, the vast majority of poly-GP and 
poly-PR inclusions co-stained with p62 (Fig. 3b, third 
row and Fig. S7b).
Moreover, double immunostaining of p62 and nucleolin 
revealed no colocalization of ubiquitinated inclusions and 
the nucleolus (Fig. 3c). However, occasionally p62 labeling 
was observed next to the nucleolus, which was consistent 
with the findings for specific DPR antibodies (Fig. 1b). 
Together, these findings indicate that in patients with 
C9orf72 mutation most intranuclear DPRs aggregate in a 
p62-positive para-nucleolar compartment and not directly 
within the nucleolus.
Fig. 2  Para-nucleolar poly-GA 
inclusions colocalize with 
transcriptionally silenced 
DNA. Immunofluorescence 
for poly-GA proteins with the 
indicated antibodies and dyes 
to label DNA or RNA in frontal 
cortex of cases with C9orf72 
mutation. a Para-nucleolar poly-
GA inclusions are enriched 
for heterochromatin labeled 
with the DNA-specific dye 
DAPI (arrow). b Para-nucleolar 
poly-GA inclusions are also 
stained with RNA-selective dyes 
SYTO12 and SYTO RNAselect. 
Note that both dyes also show 
chromatin staining similar to 
DAPI indicating cross-reactivity 
with DNA. c Nuclear poly-
GA inclusions colocalize with 
histone 3 dimethylated at lysine 
9 (H3K9me2), a marker for 
transcriptionally inactive DNA. 
Scale bars represent 10 µm
DAPI GA (5E9) MergeNucleolin
DAPI GA (5E9) H3K9me2 Merge
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Poly‑GR and poly‑GP inclusion types resemble 
poly‑GA pathology and also occur in glia
To further analyze the correlation of DPR inclusions with 
neurodegeneration, we characterized the spectrum of poly-
GR, poly-GP and poly-PR pathology in C9orf72 mutation 
patients. Poly-GR (7H1), poly-GP (7A5) and poly-PR (32B3) 
antibodies labeled predominantly NCIs throughout the brain, 
which showed the characteristic star-shaped appearance in 
pyramidal cells of the hippocampal formation and cortical 
neurons (Fig. 4a–c). Additionally, NIIs and “pre-inclusions” 
with diffuse cytoplasmic staining were also detected with all 
three DPR antibodies (Fig. 4d–i). Only poly-GR and poly-GP 
antibodies also detected DNs (Fig. 4j, k). Additionally, poly-
GP antibodies occasionally visualized diffuse pan-nuclear 
DPR expression (Fig. 4l), resembling the pattern of recombi-
nant poly-GP expression in neurons (Figs. 1a, 3a, S3).
Although DPR proteins had previously been described 
exclusively in neurons, we noticed intranuclear inclu-
sions in ependymal cells of the spinal cord central canal in 
C9orf72 cases with MND most prominently with poly-GA 
antibodies (Fig. 4m, n), but also with poly-GR and poly-
GP antibodies (Fig. 4o, p). Such glial inclusions were not 
detected in an FTLD–MND–FUS case confirming anti-
body specificity (Fig. S7c). Strikingly, the vast majority 
of these inclusions were intranuclear, while most neuronal 
DPR inclusions were cytoplasmic. In contrast to neu-
ronal intranuclear DPR inclusions, the ependymal inclu-
sions were not associated to the nucleolus (Fig. S7d). We 
observed further glial intranuclear poly-GA inclusions in 
ependymal and subependymal cells lining the lateral ven-
tricle (Fig. 4q). Thus, not only TDP-43 pathology but also 



















Primary hippocampal neurons C9orf72 frontal cortex
Fig. 3  Differential colocalization of DPR and p62 inclusions in cases 
with C9orf72 mutation and cell culture. Double immunofluorescence 
for DPR proteins and p62. Nuclei are labeled with DAPI. a In pri-
mary hippocampal neurons transduced with GA175-GFP, GFP-GR149 
or GP80-V5/His (DIV6 + 7) p62 co-aggregates with cytoplasmic and 
intranuclear poly-GA inclusions, but not with poly-GR and poly-GP. 
In contrast to poly-GA inclusions, poly-GR and poly-GP aggregates 
appear less compact or granular. b In frontal cortex of C9orf72 muta-
tion patients almost all poly-GA and poly-GR and all poly-GP inclu-
sions are positive for p62 (orange arrows). Poly-GA and poly-GR 
inclusions without p62 labeling are rare (white arrows). c Intranuclear 
p62 aggregates show the same distribution pattern as DPR inclusions 
and are mostly para-nucleolar (arrow). Scale bars represent 20 µm
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Taken together, the poly-GR and poly-GP inclusion 
pattern resembled that of poly-GA in C9orf72 mutation 
patients [10, 29, 38]. Poly-PR inclusions were very rare and 
were not found in DNs. The identification of different types 
of inclusions in neuronal and glial cells suggests cell type-
dependent differences in DPR aggregation or degradation.
Spectrum and distribution of DPR inclusions
To further elucidate the spectrum of DPR pathology in 
C9orf72 mutation patients, we analyzed the load of NCI, 
NII and DN pathology in 36 CNS regions using monoclo-






































Fig. 4  Spectrum of DPR pathology in neurons and glial cells of 
patients with C9orf72 mutation. a–l Immunohistochemistry with 
novel monoclonal antibodies for poly-GR (clone 7H1), poly-GP 
(clone 7A5) and poly-PR (clone 32B3) in cases with C9orf72 muta-
tion. Poly-GR, poly-GP and poly-PR mainly form compact character-
istic star-like cytoplasmic (a–c) or small round intranuclear inclusions 
(arrows in d–f) in neurons and show a diffuse granular cytoplasmic 
staining (g–i). Furthermore there are poly-GR and poly-GP aggre-
gates in dystrophic neurites (j, k); note that dystrophic neurites with 
poly-PR could not be detected. Solely for poly-GP, a diffuse pan-
nuclear staining is also found (l). m–q Immunohistochemistry with 
indicated DPR antibodies shows glial intranuclear inclusions in 
C9orf72 cases. In ependymal cells of spinal cord central canal intra-
nuclear inclusions of poly-GA (m, n detail of m), and less frequently 
of poly-GR (o) and poly-GP (p) are detectable; further glial intranu-
clear inclusions of poly-GA are present in ependymal (arrow) and 
subependymal (arrowhead) cells of the lateral ventricle wall at level 
of accumbens nucleus (q). Scale bars represent 20 µm. Am amyg-
dala, CA cornu ammonis region, DN dystrophic neurite, Ent entorhi-
nal cortex, FCtx frontal cortex, GII glial intranuclear inclusion, MCtx 
primary motor cortex, LV wall of lateral ventricle, NCI neuronal 
cytoplasmic inclusion, NII neuronal intranuclear inclusion, SC spinal 
cord, SCcc spinal cord central canal
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7H1) and poly-GP (clone 7A5) in five representative cases 
with comprehensive tissue collection, including two MND 
cases and three FTLD/MND cases (C9-1 to C9-5, see 
Table 1). Overall poly-PR distribution pattern appeared 
similar (not shown), but the number of inclusions was too 
low for a reliable semi-quantitative analysis.
In all brain regions, DPR inclusion pathology in form 
of NCIs, NIIs and DNs was most abundant for poly-
GA (Fig. 5a) and less distinct for poly-GR and poly-GP 
(Fig. 5b, c; Table S1). Regardless of the neuropathological 
diagnosis, all cases showed the strongest DPR pathology in 
neocortex, hippocampus and cerebellum. DPR inclusions 
were also abundant in amygdala and thalamus. Few inclu-
sions were visible in basal ganglia, brain stem and spinal 
cord. Overall, DNs with poly-GR aggregates were less fre-
quent than those with poly-GA or poly-GP aggregates. The 
highest density of poly-GA or poly-GP containing DNs 
was seen in the molecular layer of the cerebellum. Despite 
the abundant intranuclear inclusions of overexpressed 
poly-GR in various cell models, poly-GR NIIs were even 
less frequent than poly-GA and poly-GP NIIs in C9orf72 
mutation patients. Poly-GR NIIs were most abundant in 
the thalamus compared to poly-GR NCIs. Thus, the pat-
tern of poly-GA, poly-GR and poly-GP inclusions pathol-
ogy is consistent with previous less detailed reports [1, 29, 
36]. The biggest difference between the three sense strand-
derived DPR species was the almost complete lack of poly-
GR DNs throughout the CNS.
Poly‑PR but not poly‑GR inclusions show different 
distribution in FTLD and MND cases
To better analyze the correlation of poly-GR and poly-PR 
pathology with neurodegeneration, we focused on seven 
key regions that are variably affected in C9orf72 mutation 
patients. We counted the number of inclusions in a defined 
number of visual fields in three neocortical regions (cor-
tex of the medial frontal gyrus, motor cortex striate area 
of the occipital cortex), two hippocampal regions (granu-
lar cell layer of the dentate gyrus, pyramidal cell layer 
of cornu ammonis regions 3 and 4) and the granular and 
molecular cell layers of the cerebellar cortex (for details 
see methods). Compared to the semi-quantitative analysis 
(Fig. 5), we used a larger cohort of 14 patients, including 
three MND cases, three FTLD cases and eight patients 
with combined FTLD/MND (Table 1). Strikingly, poly-GR 
load was similar in occipital cortex, which is not affected 
by neurodegeneration in any of the three patient groups, 
and in frontal cortex, which is degenerated in FTLD and 
FTLD/MND cases, but not in MND cases (Fig. 6a; Table 
S2). In contrast, DPR abundance was less in the motor 
cortex than in frontal or occipital cortex, although we did 
not have material for comparison from patients without 
neuropathological signs of MND. Overall, poly-GR inclu-
sions showed a very similar distribution pattern among all 
three patient subgroups, suggesting that poly-GR aggrega-
tion does not spatially correlate with neurodegeneration in 
C9orf72 mutation patients.
Poly-PR inclusions were scarce throughout the CNS 
with the highest frequency in the hippocampus. In three 
cases (MND and FTLD/MND, 6 sections each), we found 
no poly-PR in spinal cord motoneurons. Poly-PR was sig-
nificantly more abundant in the CA3/4 region of FTLD 
cases compared to MND cases (Fig. 6b). Thus, poly-PR, 
but not poly-GR, distribution differs between C9orf72 dis-
ease subtypes, although it is not spatially correlated with 
neurodegeneration.
Spectrum of Unc119 inclusion pathology
Next, we analyzed the distribution of Unc119, a transport 
factor for myristoylated proteins, which co-aggregates 
with poly-GA [34]. In our previous analyses, Unc119 
inclusions were more prominent in regions affected by 
prominent neurodegeneration in three C9orf72 mutation 
patients, but staining intensity and inclusions density var-
ied considerably between patients. To improve detection of 
Unc119 inclusions, we tested several conditions for antigen 
retrieval (see method section for details). Brief proteinase 
K treatment completely removed the diffuse Unc119 stain-
ing in the neuronal soma of patients and controls, but dra-
matically increased visible Unc119 inclusion pathology in 
C9orf72 mutation patients (Fig. 7). Using this improved 
staining protocol, we identified abundant Unc119 inclu-
sions not only in the frontal cortex, the dentate gyrus but 
also in the cerebellum (Fig. 7a–c). Rare Unc119 inclusions 
were also seen in the cytoplasm of spinal cord motoneu-
rons (Fig. 7d) and in the nuclei of central canal ependymal 
cells (Fig. 7e). No Unc119 inclusions were found in con-
trol cases (Fig. 7f–j). The spectrum of proteinase K resist-
ant Unc119 pathology ranged from predominant NCIs 
to less abundant NIIs and DNs and to rare diffuse aggre-
gates (Fig. 7k–n). Moreover, para-nucleolar Unc119 inclu-
sions colocalizing with poly-GA were found, indicating 
that Unc119 can be recruited into the nucleus by poly-GA 
aggregates (Fig. S8). Overall, the pattern of Unc119 pathol-
ogy in cases with C9orf72 mutation strongly resembled the 
pattern of DPR pathology.
Regional distribution of poly‑GA and Unc119 
inclusions differs between MND and FTLD cases
To analyze the correlation of Unc119 aggregation and neu-
rodegeneration, we extended our analysis to further CNS 
regions in the five representative cases (C9-1 to C9-5, see 
Table 1). We found many Unc119 inclusions throughout 






















































































































































































































































































































































Fig. 5  Regional distribution pattern of neuronal poly-GA, poly-GR 
and poly-GP inclusion pathology in cases with C9orf72 mutation. 
Semi-quantitative immunohistochemical analyses for poly-GA (a), 
poly-GR (b) and poly-GP (c) neuronal cytoplasmic inclusions (NCI), 
neuronal intranuclear inclusions (NII) and dystrophic neurites (DN) 
in representative cortical, hippocampal, subcortical, brain stem, cer-
ebellar and spinal cord areas of five C9orf72 mutation patients reveal 
a predominance of poly-GA aggregates for all types of aggregates in 
all areas. Highest densities of poly-GA, poly-GR and poly-GP aggre-
gates are seen in cortical areas, hippocampus, amygdaloid nuclei, 
thalamus and cerebellum. Note that poly-GR-positive DNs are rarely 
found outside the hippocampus. Categories for semi-quantitative 
analysis (none, few, some, many, abundant) are explained in detail 
in the “Materials and methods” section. Acc accumbens nucleus, 
Am amygdaloid nuclei, BC basal nucleus of Meynert compact part, 
CA3/4 cornu ammonis fields 3/4, CBLgl cerebellar granular cell layer, 
CBLml cerebellar molecular cell layer, CBLpcl cerebellar Purkinje 
cell layer, CCtx cortex of cingulate gyrus, Cd caudate nucleus, DG 
dentate gyrus, DRN dorsal raphe nuclei, FCtx frontal cortex, IO 
inferior olive, LC locus coeruleus, MCtx primary motor cortex, N 
XII hypoglossal nucleus, OCtx occipital cortex, Pa pallidum, PCtx 
parietal cortex, PN pontine nuclei of pons, preEnt lamina principa-
lis externa of entorhinal cortex, priEnt lamina principalis interna of 
entorhinal cortex, Pu putamen, SCAc anterior horn of cervical spinal 
cord, SCAl anterior horn of lumbar spinal cord, SCAs anterior horn of 
sacral spinal cord, SCAt anterior horn of thoracic spinal cord, SCPc 
posterior horn of cervical spinal cord, SCPl anterior horn of lumbar 
spinal cord, SCPs posterior horn of sacral spinal cord, SCPt posterior 
horn of thoracic spinal cord, SNc substantia nigra compact part, STN 
subthalamic nucleus, SubCA1/2 subiculum plus cornu ammonis fields 
1/2, TCtx temporal cortex, Th thalamus
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the neocortex, hippocampus and thalamus (Fig. 8a; Table 
S1). In contrast to findings using our previous staining pro-
tocol, Unc119 inclusions were now also frequent in the cer-
ebellum. Overall, Unc119 distribution closely resembled 
poly-GA distribution (Fig. 5a), although Unc119 inclusions 
were less frequent in all brain regions (Fig. 8a). Unc119 
NIIs were most prominent in the dentate gyrus and com-
pletely absent in the brain stem.
A quantitative analysis of the complete patient cohort 
revealed no difference in the poly-GA and Unc119 fre-
quency in cortical regions and hippocampus between the 
MND, FTLD or FTLD/MND patients (Fig. 8b, c; Table 
S2). As for poly-GR (Fig. 6a), the poly-GA load was simi-
lar in the non-degenerating occipital cortex and the degen-
erating frontal cortex of FTLD and FTLD/MND patients 
(Fig. 8b). Unexpectedly, poly-GA and Unc119 inclusions 
were significantly more common in the cerebellar granular 
cell layer of FTLD patients compared to MND or FTLD/
MND patients (Fig. 8b, c). Interestingly, these patients 
showed a trend towards lower levels of poly-GR inclusions 
(Fig. 6a), suggesting differential translation or aggregation 
of these DPR species in the cerebellum. These findings are 
consistent with an emerging role of the cerebellum in the 
pathophysiology of C9orf72 disease [13, 14, 30–32, 52, 
56].
Discussion
With this study, we provide the first quantitative analysis of 
the three major DPR species poly-GA, poly-GR and poly-
GP as well as poly-PR in a neuropathologically character-
ized cohort of C9orf72 mutation patients using monoclonal 
antibodies. Despite ample in vitro evidence especially for 
poly-GA, poly-GR and poly-PR toxicity [23, 34, 35, 50, 
55, 57, 59, 60], we could not identify a spatial correlation 
between DPR inclusion pathology and neurodegeneration 
in patients, although poly-GA and poly-PR showed differ-
ent distribution in MND and FTLD cases. Different locali-
zation and aggregation behavior especially of poly-GR 
and poly-PR proteins in cellular models and patients may 
explain the poor translatability of the in vitro results. The 
newly identified para-nucleolar aggregation of DPR pro-
teins in heterochromatin structures in patient neurons hints 
for repeat-associated alterations in transcription.
Subcellular localization of DPR proteins
In patients, poly-GA, poly-GR, poly-GP and poly-PR 
showed remarkably similar regional and subcellular expres-
sion patterns, suggesting that these proteins are co-trans-
lated in most cells and then co-aggregate in p62-positive 
inclusions [38]. In transduced primary neurons, only poly-
GA expression gives rise to p62-positive compact cyto-
plasmic inclusions. Consistent with previous reports over-
expressed poly-GR and poly-PR predominantly localized 
to the nucleolus and was p62 negative in primary neuron 
culture [34, 50, 57]. However, in patients with C9orf72 
mutation, poly-GR and poly-PR inclusions were predomi-
nantly cytoplasmic, and we did not find a single nucleolar 
inclusion. Overexpression of poly-GP in neurons resulted 
either in diffuse cytoplasmic or more often diffuse pan-
nuclear accumulation similar to previous reports [57]. We 
found both expression patterns in patients, although com-

































































Fig. 6  Quantitative assessment of poly-GR and poly-PR inclu-
sion pathology in selected brain areas of C9orf72 cases with differ-
ent neuropathological phenotypes. The graphs show the minimum, 
mean and maximum number of poly-GR and poly-PR inclusions 
averaged per visual field. a There is no significant difference in the 
average number of cytoplasmic and intranuclear neuronal poly-GR 
inclusions per visual field (20× objective, 40× for cerebellar granular 
cell layer) between C9orf72 cases with motoneuron disease (MND, 
n = 2–3), cases with frontotemporal lobar degeneration (FTLD, 
n = 3, no MtCtx) and cases with a combination of frontotemporal 
lobar degeneration and motoneuron disease (FTLD/MND, n = 4–8) 
in brain areas with highest poly-GR load. b Poly-PR inclusions are 
only common in hippocampus and cerebellum of FTLD and FTLD/
MND cases, but absent in MND cases, reaching statistical signifi-
cance in CA3/CA4 (ANOVA, p = 0.0103). The quantitative analy-
sis is explained in detail in the “Materials and methods” section. 
The data for individual cases are presented in Table S2. CA3/4 cornu 
ammonis fields 3/4, CBLgl cerebellar granular cell layer, CBLml cer-
ebellar molecular cell layer, DG dentate gyrus, FCtx frontal cortex, 
MCtx primary motor cortex, OCtx occipital cortex
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We noticed abundant poly-GA pathology in ependy-
mal cells of the spinal cord central canal and the lateral 
ventricle. Poly-GP and poly-GR were detected at a lesser 
extent. While TDP-43 pathology and RNA foci have been 
detected in neurons and glia [17], DPR proteins had been 
described only in neurons and in Sertoli cells of testis so 
far [1, 38]. In contrast to neurons, ependymal cells harbor 
almost exclusively intranuclear inclusions. The pathogenic 
role of glial DPR inclusions remains unclear, since it does 
not extend to astrocytes and oligodendrocytes [29]. How-
ever, trophic support from ependymal cells has been linked 
to ALS either directly or via altering neurogenesis [6, 12]. 
Moreover, poly-GP has been detected in the CSF, which 
may reflect neuronal death or active secretion [47]. Addi-
tionally, ependymal cells may release DPR proteins into the 
CSF more efficiently than neurons.
Since the localization of DPR aggregates is already 
differing between neurons and glia in patients, cell type-
specific effects may contribute to the aberrant expression 
pattern of overexpressed poly-GR and poly-GP in cellular 
models. Further explanations may be the faster expression 
kinetics and the lack of expression of the other DPR species 
and hexanucleotide repeat RNA in most current model sys-
tems. Since aberrantly localized DPR proteins may invoke 
different toxic pathways, future studies of cellular and 
animal models of DPR toxicity will benefit from the careful 
analysis of the subcellular localization of the aggregates.
Para‑nucleolar DPR aggregates and nucleolar stress
While intranuclear DPR inclusions appear randomly dis-
tributed throughout the nucleus in glia, we noticed that 
intranuclear inclusions in neurons are predominantly para-
nucleolar. To elucidate the function of para-nucleolar DPR 
aggregates, we tested several markers for known nucleolus-
associated compartments. Robust co-staining with p62 is 
reminiscent of the ubiquitinated Marinesco bodies, found 
in the aging brain particularly in neuromelanin containing 
neurons of the substantia nigra [3, 40]. However, the para-
nucleolar DPR inclusions lack the characteristic eosino-
philic staining and we could not detect colocalization with 
HDAC6, which had previously been identified in Mari-
nesco bodies [40]. The “perinucleolar compartment” has 
been implicated in RNA polymerase III-dependent tran-
scription [41], but the marker proteins CUG-BP1, PML, 
HSF1 and CD99 did not colocalize with DPR NIIs. In cells 
with elevated proteasomal activity, proteasomes congre-
gate in “clastosomes” close to the nucleolus [24], but the 
para-nucleolar DPRs were negative for proteasomal subu-
nits PSMC2 and PSMC4. Block of transcription leads to a 
C9 NCI C9 NII C9 DN C9 diffuseEnt Ent EntCA1/2
9C9C 9C9C C9
a b c d e
f g h i j
k l m n
lgLBCxtCF ccCSCSGD
lrtClrtC lrtClrtClrtC lgLBCxtCF ccCSCSGD
Fig. 7  Spectrum of Unc119 pathology in cases with C9orf72 muta-
tion resembles poly-GA pathology. Immunohistochemistry with a 
polyclonal rabbit antibody against Unc119. In C9orf72 mutation 
cases, numerous Unc119 inclusions are seen in neurons of various 
brain areas (a–c), rarely in motoneurons of spinal cord (d) and in 
ependymal cells of spinal cord central canal (e); examples of cyto-
plasmic inclusions are marked by arrows. (f–j) Corresponding areas 
of control cases do not contain such inclusions and the proteinase K 
pretreatment removes all soluble Unc119 staining in cases and con-
trols. (k–n) The types of Unc119 aggregates are similar to those of 
DPR proteins. There are often star-like neuronal cytoplasmic inclu-
sions (NCI) (k), neuronal intranuclear inclusions (NII, pointed by 
arrow in l), compact aggregates in dystrophic neurites (DN) (m) 
and diffuse granular cytoplasmic aggregates in neurons (n). Scale 
bars represent 20 µm. C9 case with C9orf72 mutation, CA1/2 cornu 
ammonis fields 1/2, CBLgl granular cell layer of cerebellum, Ctrl 
control case, DG dentate gyrus, Ent entorhinal cortex, FCtx frontal 
cortex, SC spinal cord, SCcc spinal cord central canal
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segregation of nucleolar subcompartments and formation 
of the so-called “nucleolar caps”, but the marker proteins 
fibrillarin, PML and coilin were not detected in DPR inclu-
sions [45].
Colocalization of para-nucleolar DPR proteins with 
heterochromatin in DAPI staining and with H3K9me2, a 
prominent marker of transcriptional repression, suggests a 
link between DPRs and transcriptional regulation. This is 
most consistent with transcriptional stalling and nucleolar 
stress due to formation of RNA·DNA hybrids (so-called 
R-loops) from hexanucleotide repeats [20]. Importantly, 
H3K9 dimethylation has been linked to R-loop-induced 
transcriptional silencing [46]. This potential link of DPR 
proteins with DNA/RNA-based disease mechanisms may 
also explain why para-nucleolar DPR aggregates were not 
found in transduced neurons expressing DPR proteins from 
synthetic genes. We found no colocalization of para-nucle-
olar DPR inclusions with GGGGCC repeat RNA foci. Con-
sistent with previous reports, there was rather an inverse 
correlation of foci and (cytoplasmic) DPR inclusions [17]. 
Nucleolar stress is typically associated with nucleolar 
enlargement and nucleolar accumulation of p53 particu-
larly when it is caused by proteasomal inhibition [21, 26]. 


























































































































































Fig. 8  Distribution of poly-GA and Unc119 inclusion pathology 
depends on pathological subtypes. a Semi-quantitative analysis of 
Unc119 neuronal cytoplasmic inclusions (NCI), neuronal intranu-
clear inclusions (NII) and dystrophic neurites (DN) in representative 
cortical, hippocampal, subcortical, brain stem, cerebellar and spinal 
cord areas of five C9orf72 mutation patients. The regional distribu-
tion of Unc119 inclusions resembles the pattern of poly-GA pathol-
ogy (Fig. 5), albeit at overall lower abundance. Semi-quantitative 
analysis is explained in detail in the “Materials and methods” sec-
tion. Abbreviations as in Fig. 5. b, c Quantitative analysis of NCI and 
NII of poly-GA and Unc119 pathology by immunohistochemistry in 
C9orf72 mutation patients with MND (n = 2–3), FTLD (n = 3, no 
MtCtx) and combined FTLD/MND (n = 4–8) cases as in Fig. 6. The 
graphs show the minimum, mean and maximum number of poly-
GA and Unc119 inclusions averaged per visual field. Poly-GA dis-
tributions are significantly different between FTLD, FTLD/MND 
and MND patients in granular layer of cerebellum (p(FTLD vs. FTLD/
MND) = 0.0003, p(FTLD vs. MND) = 0.0003) (b). Similarly, the frequency 
of Unc119 inclusions is different in the granular layer of cerebellum 
in FTLD patients compared with FTLD/MND and MND (p(FTLD vs. 
FTLD/MND) = 0.0005, p(FTLD vs. MND) = 0.0008) (c). Quantitative analy-
sis is explained in detail in the “Materials and methods” section, the 
data for individual cases are presented in Table S2. Abbreviations as 
in Fig. 6
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by poly-GA in vitro [57, 59]. However, we detected no 
nucleolar accumulation of p53 and no change in nucleolar 
size and morphology in C9orf72 patients. Thus, neither the 
C9orf72 mutant allele nor cytoplasmic or para-nucleolar 
DPR inclusions affected nucleolar size in the brain.
Correlation of DPR and Unc119 inclusion pathology 
with neuropathological subtypes
Our cohort of 14 C9orf72 mutation patients represents the 
whole spectrum of clinical and neuropathological subtypes, 
including three cases each with either MND or FTLD and 
eight cases with a mixed disease. We chose five representa-
tive cases with comprehensive tissue collection for the 
semi-quantitative analysis of 36 CNS regions of the sense 
strand-derived DPR species and Unc119. We had previ-
ously shown that poly-GA sequesters Unc119, a protein 
that regulates trafficking of lipidated cargo proteins, such 
as transducin α in the retina [34, 58]. Loss of Unc119 is 
neurotoxic and Unc119 overexpression rescues poly-GA 
toxicity in vitro. Using improved antigen retrieval with 
proteinase K, we could detect Unc119 in about 40 % of 
poly-GA inclusions in all analyzed brain regions. Although 
these data corroborate Unc119 as a specific component of 
poly-GA inclusions, selective co-aggregation of Unc119 
cannot easily explain selective vulnerability in certain brain 
regions. However, proteinase K pretreatment precludes 
analyzing the residual soluble Unc119 in affected cells. 
Identification of Unc119 cargos essential for neuronal sur-
vival and analysis of their localization in C9orf72 patients 
will be necessary to determine functional Unc119 inactiva-
tion and its correlation to neurodegeneration.
In all patients, DPR and Unc119 pathology showed a 
stereotypic expression pattern with highest abundance in 
cortex, hippocampus, thalamus and cerebellum. In contrast 
to previous semi-quantitative studies restricted to poly-GA 
pathology [10, 29], we performed a quantitative analysis 
of poly-GA, poly-GR, poly-PR and Unc119 pathology in 
seven critical brain regions in all 14 patients. The amount 
of poly-GA, poly-GR, poly-PR and Unc119 aggregates was 
similar in frontal cortex, motor cortex and occipital cortex, 
although the latter is not affected by neurodegeneration in 
C9orf72 mutation patients. Moreover, the extent of DPR 
pathology in frontal cortex and motor cortex did not cor-
relate with neurodegeneration in FTLD or MND cases. 
Interestingly, poly-GA and poly-PR, the DPR species with 
the strongest toxic effects in cell culture, showed distinct 
depositions in FTLD vs. MND cases with C9orf72 muta-
tion cases [34, 35, 55, 57, 59]. Poly-PR aggregates were 
significantly more common in the CA3/4 region of FTLD 
than of MND cases. Due to the very low frequency of poly-
PR inclusions, the pathophysiological relevance remains 
unclear. Interestingly, nuclear foci of antisense repeat RNA 
have recently been linked to motor neuron degeneration [8]. 
Poly-GA and Unc119 pathology was significantly higher in 
the cerebellar granular cell layer of FTLD patients com-
pared to MND and FTLD/MND patients. At the same time, 
there was a trend for lower poly-GR pathology in FTLD 
patients, which suggests that the composition of the DPR 
inclusions in these patients is significantly altered, although 
it is unclear if and how this is related to pathogenesis. In 
our previous study, focusing on poly-GA pathology no sim-
ilar correlation was observed [29], but both studies differ 
in staging of the cases (clinically vs. neuropathologically) 
and in analyzing the extent of DPR pathology (semi-quan-
titative vs. quantitative approaches). Interestingly, there 
is considerable somatic heterogeneity in the length of the 
expanded C9orf72 repeat and only the repeat length in the 
cerebellum but not in the frontal cortex is inversely corre-
lated with disease duration, arguing for an underappreci-
ated role of the cerebellum in the pathogenesis of FTLD 
[49, 52].
Overall, our data do not support a spatial correlation of 
DPR inclusions with neurodegeneration, although DPR 
proteins can clearly induce neurotoxicity in various model 
systems. Several explanations are possible:
1. DPR inclusions are not actually involved in the 
C9orf72 pathomechanism but only TDP-43 inclusions. 
The strongest counterarguments are rare C9orf72 cases 
without TDP-43 pathology and abundant DPR pathol-
ogy [2, 36, 38, 42]. In addition, DPR pathology seems 
to precede TDP-43 pathology, although it is not spa-
tially correlated [2, 33]. Moreover, introducing stop 
codons into the GGGGCC repeat expansion prevented 
toxicity in the fly model, strongly arguing for a critical 
role of DPR proteins [35]. Methylation in the C9orf72 
promoter region is associated with reduced RNA foci 
and DPR pathology and prolonged disease duration 
presumably by inhibition of repeat transcription, which 
supports a toxic gain of function pathomechanism [4, 
28, 44].
2. Soluble DPR proteins, rather than inclusions, may 
cause neurodegeneration. Although diffuse poly-GA 
coalesces into inclusions in cell culture systems [59], 
it remains unclear whether DPR proteins in cells with 
diffuse staining patterns cause enhanced toxicity. Solu-
ble poly-GR/PR may interfere with the overall cellular 
RNA metabolism [23]. Intercellular spreading of DPR 
proteins may trigger pathogenic mechanisms leading to 
TDP-43 phosphorylation or seed TDP-43 aggregation 
in a non-cell autonomous manner. Spreading and seed-
ing have been reported for other intracellular aggregat-
ing proteins in neurodegenerative diseases, but have 
not been claimed to be the main source of toxicity [22, 
53].
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3. Finally and most likely, a combination of DNA•RNA 
hybrids, RNA foci and protein toxicity, together with a 
potential C9orf72 haploinsufficiency and unknown cell 
type-specific susceptibility factors are responsible for 
the selective neurodegeneration in certain brain regions 
in C9orf72 mutation carriers. This is supported by a 
very recent mouse model showing TDP-43 pathology, 
neurodegeneration, RNA foci and DPR proteins upon 
high-level viral expression of the GGGGCC repeat [5].
This interaction of DNA/RNA toxicity and DPR toxicity 
may be represented by the newly described para-nucleolar 
DPR aggregates. Thus, models expressing both repeat RNA 
and DPR proteins and constant comparison with pathologi-
cal analysis of patient samples are needed to elucidate the 
cause of neurodegeneration in C9orf72 repeat expansion 
carriers, and how this can lead to either FTLD or MND.
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